secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2026-05-18T13:04:56+00:00
Accession:  0001193125-26-228013
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.03, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine completes $2.9B acquisition of Soleno Therapeutics, adds VYKAT XR for Prader-Willi
--------------------------------------------------------------------------------

- Tender offer accepted 46.4M shares (88.9% of Soleno) at $53/sh cash; total equity value ~$2.9B.
- Merger completed May 18, 2026; Soleno becomes wholly owned subsidiary; shares to be delisted from Nasdaq.
- VYKAT XR (diazoxide choline) is first approved therapy for hyperphagia in Prader-Willi syndrome (ages 4+).
- Entered $1.0B senior secured revolving credit facility (5-yr); initial $600M drawn; SOFR + 1.125%-1.75% margin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000119312526228013/0001193125-26-228013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000119312526228013/d94926d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-228013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer